A Pilot Trial of Clazakizumab in Late ABMR

Part A:

Patients positive for anti-HLA donor-specific antibodies (DSA) and with biopsy-proven late ABMR (Acute/active or chronic/active phenotype according to the Banff 2015 classification) will be identified and recruited at the kidney transplantation outpatient services of the two center sites. Participants will be randomized to receive either clazakizumab or placebo subcutaneously (1:1 randomization stratified for ABMR type) for a period of 12 weeks (administration of clazakizumab/placebo at day 0, and after 4 and 8 weeks). After 12 weeks, patients will be subjected to a first follow-up biopsy. Primary goals of this part of the trial are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a short course of treatment. Moreover, part A will allow for a first preliminary assessment of the impact of clazakizumab on ABMR-associated inflammation detected in peripheral blood and in the rejecting organ allograft, on the pharmacokinetics of pantoprazole as a probe drug to investigate influence of IL-6 blockade on cytochrome P450 (CYP) dependent drug metabolism (potential effects on the half-life of CYP-metabolized drugs such as pantoprazole, and on the short-term course of DSA mean fluorescence intensity (MFI) and kidney allograft function (eGFR, urinary protein excretion). The randomization sequence will be unblinded for a first data analysis after the last patient has completed the 12-week follow-up period.

Part B:

After completion of part A after 12 weeks, all study patients will enter part B, an open-label part of the study. All 20 subjects will receive subcutaneous clazakizumab in 4-weekly intervals until the end-of-study (EOS) visit after 52 weeks and will then be subjected to a second protocol biopsy. Major goals of part B are to evaluate the safety and tolerability of a prolonged period of treatment with clazakizumab and the long-term impact of this antibody on the evolution of ABMR, rejection-associated biomarkers and kidney allograft function and survival over a period of 12 months.

Inclusion criteria

• Voluntary written informed consent
• Age >18 years
• Functioning living or deceased donor allograft after ≥365 days post-transplantation
• eGFR >30 ml/min/1.73 m2
• Detection of HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).
• Acute/active or chronic/active ABMR (±C4d in PTC) according to Banff 2013/2015
• Molecular ABMR score (ABMRpm) ≥0.2

Exclusion criteria

• Patients actively participating in another clinical trial
• Age ≤18 years
• Female subject is pregnant or lactating
• Index biopsy results:
• T-cell-mediated rejection classified Banff grade ≥I
• De novo or recurrent severe thrombotic microangiopathy
• Polyoma virus nephropathy
• De novo or recurrent glomerulonephritis
• Acute rejection treatment <3 month before screening
• Acute deterioration of graft function (eGFR decline within 1-3 months >25%)
• Nephrotic range proteinuria >3500 mg/g protein/creatinine ratio
• Active viral, bacterial or fungal infection precluding intensified immunosuppression
• Active malignant disease precluding intensified immunosuppressive therapy
• Abnormal liver function tests (ALT, AST, bilirubin > 1.5 x upper limit of normal)
• Other significant liver disease
• Latent or active tuberculosis (positive QuantiFERON-TB-Gold test, Chest X-ray)
• Administration of a live vaccine within 6 weeks of screening
• Neutropenia (<1 G/L) or thrombocytopenia (<100 G/L)
• History of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease
• Allergy against proton pump inhibitors
• History of alcohol or illicit substance abuse
• Serious medical or psychiatric illness likely to interfere with participation in the study